Sociodemographic disparities in ophthalmological clinical trials.

Luis Filipe Nakayama, William Greig Mitchell, Skyler Shapiro, Alvina Pauline D Santiago, Warachaya Phanphruk, Khumbo Kalua, Leo Anthony Celi, Caio Vinicius Saito Regatieri

Journal: BMJ open ophthalmology 2023;8(1):e001175

PMID: 37278426

Abstract

INTRODUCTION

In ophthalmology, clinical trials (CTs) guide the treatment of diseases such as diabetic retinopathy, myopia, age-related macular degeneration, glaucoma and keratoconus with distinct presentations, pathological characteristics and responses to treatment in minority populations.Reporting gender and race and ethnicity in healthcare studies is currently recommended by National Institutes of Health (NIH) and Food and Drug Administration (FDA) guidelines to ensure representativeness and generalisability; however, CT results that include this information have been limited in the past 30 years.The objective of this review is to analyse the sociodemographic disparities in ophthalmological phases III and IV CT based on publicly available data.

METHODS

This study included phases III and IV complete ophthalmological CT available from clinicaltrials.org, and describes the country distribution, race and ethnicity description and gender, and funding characteristics.

RESULTS

After a screening process, we included 654 CTs, with findings that corroborate the previous CT reviews' findings that most ophthalmological participants are white and from high-income countries. A description of race and ethnicity is reported in 37.1% of studies but less frequently included within the most studied ophthalmological specialty area (cornea, retina, glaucoma and cataracts). The incidence of race and ethnicity reporting has improved during the past 7 years.

DISCUSSION

Although NIH and FDA promote guidelines to improve generalisability in healthcare studies, the inclusion of race and ethnicity in publications and diverse participants in ophthalmological CT is still limited. Actions from the research community and related stakeholders are necessary to increase representativeness and guarantee generalisability in ophthalmological research results to optimise care and reduce related healthcare disparities.

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Address: Laboratory for Computational Physiology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA [email protected].; Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil.; Ophthalmology, The Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia.; Laboratory for Computational Physiology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.; Cornell University, Ithaca, New York, USA.; Department of Ophthalmology and Visual Sciences, Philippine General Hospital, Manila, Metro Manila, Philippines.; Ophthalmology, Khon Kaen University, Nai Mueang, Khon Kaen, Thailand.; Ophthalmology, Kamuzu University of Health Sciences, Blantyre, Southern Region, Malawi.; Biostatistics, Harvard University T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.